RVMD Q1 2021 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-12.3% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$37M-369.1% margin

Net Income

-$37M-367.0% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+15.8%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$41M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$812M

Total Liabilities

$89M

Stockholders' Equity

$723M

Cash & Equivalents

$352M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$12M	-12.3%
Gross Profit	$10M	$12M	-12.3%
Operating Income	-$37M	-$21M	-77.4%
Net Income	-$37M	-$20M	-90.5%

Revenue Segments

Collaboration Revenue

$10M100%